SEC Company Response from ANAVEX LIFE SCIENCES CORP. (AVXL) (CIK 0001314052) (AVXL) — Jun 9, 2017
ANAVEX LIFE SCIENCES CORP. (AVXL) (CIK 0001314052)
Date: June 9, 2017 · CIK: 0001314052 · Accession: 0001615774-17-003075
AI Filing Summary & Sentiment
File numbers found in text: 333-218292
Show Raw Text
CORRESP
1
filename1.htm
ANAVEX LIFE SCIENCES CORP.
51 W. 52nd Street, 7th Floor
New York, NY 10019-6163
June 9, 2017
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Hillary Daniels
Re:
Anavex Life Sciences Corp.
Request for Acceleration of Registration Statement on Form S-3
File No. 333-218292
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anavex Life Sciences Corp., a Nevada corporation
(the “Company”), hereby requests acceleration of the effectiveness of its Registration Statement on Form S-3
(File No. 333-218292), filed with the U.S. Securities and Exchange Commission on May 26, 2017, to 4:00PM ET on June 12, 2017
or as soon thereafter as practicable.
Please direct any
questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 of K&L Gates LLP, legal counsel to the
Company.
Sincerely,
/s/ Christopher Missling, PhD
Christopher Missling, PhD
Chief Executive Officer